Pharma Pioneer

Viking Reports Positive Phase 1 Trial Results for VK2735 Dual Receptor Agonist

19 May 2024
2 min read

Viking Therapeutics has reported significant weight loss outcomes from a Phase 1 clinical trial of VK2735, a new dual GLP-1/GIP receptor agonist. The drug, taken orally in tablet form, was found to be safe and well-tolerated over a 28-day period, with a 5.3% weight reduction from baseline and a 3.3% mean weight loss compared to placebo. The study also showed that up to 57% of subjects treated with VK2735 achieved a weight loss of at least 5%, contrasting with 0% in the placebo group. The positive results have prompted Viking to plan a Phase 2 trial for the second half of 2024, focusing on obesity treatment.
In the trial, VK2735 exhibited a dose-dependent weight reduction, with the 40 mg dose group showing the most significant results. Notably, the drug's safety profile was favorable, with all treatment-related adverse events (TEAEs) being mild or moderate, and a majority of gastrointestinal issues were also mild. No serious adverse events were reported throughout the study.
The Phase 1 study was designed to assess the drug's safety and tolerability in healthy adults with a BMI of 30 kg/m² or higher. The primary objective was met with flying colors, indicating VK2735's potential as an oral treatment for obesity with a good safety profile.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for metabolic and endocrine disorders. Along with VK2735, they are also working on VK2809, a small molecule for lipid and metabolic disorders, and VK0214, a potential treatment for X-linked adrenoleukodystrophy (X-ALD).

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

CinFina Pharma: FDA Approves CIN-110 IND for Obesity Treatment, Initiating Phase 1 Study with First Doses Administered
Pharma Pioneer
2 min read
CinFina Pharma: FDA Approves CIN-110 IND for Obesity Treatment, Initiating Phase 1 Study with First Doses Administered
19 May 2024
CIN-110 is being developed by CinFina Pharma, a company within the CinRx portfolio that focuses on treatments for obesity and metabolic disorders.
Read →
MEI Pharma Updates on Voruciclib and Venetoclax Combo in Relapsed/Refractory AML Clinical Trial
Pharma Pioneer
3 min read
MEI Pharma Updates on Voruciclib and Venetoclax Combo in Relapsed/Refractory AML Clinical Trial
19 May 2024
The study is assessing the combination of voruciclib, a CDK9 inhibitor, and venetoclax, a BCL2 inhibitor, for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).
Read →
TiumBio Files for Phase 1b Trial of Prolonged-Action rFVIIa TU7710 in Hemophilia Patients
Pharma Pioneer
3 min read
TiumBio Files for Phase 1b Trial of Prolonged-Action rFVIIa TU7710 in Hemophilia Patients
19 May 2024
This submission is for a Phase 1b clinical trial of TU7710, a novel recombinant activated factor VII (rFVIIa), intended to treat hemophilia A or B patients with inhibitors.
Read →
Opus Genetics Completes Dosing in Phase 1/2 Gene Therapy Trial for Inherited Retinal Dystrophy LCA5
Pharma Pioneer
2 min read
Opus Genetics Completes Dosing in Phase 1/2 Gene Therapy Trial for Inherited Retinal Dystrophy LCA5
19 May 2024
Opus Genetics reported positive results from its Phase 1/2 clinical trial. The trial is testing OPGx-LCA5.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.